Silence Therapeutics’ efforts to push SLN124 as a potential treatment for myelodysplastic syndrome (MDS) may have hit a roadblock earlier this year, but the FDA appears to have faith in the therapy’s abilities for another type of blood cancer. The agency granted SLN124 a fast-track tag to treat polycythemia vera (PV) ahead of a planned phase 1/2 study later this year, the company announced Thursday morning. SLN124 is designed to temporarily silence TMPRSS6, a gene that stops the liver from making hepcidin. Source: Fierce Biotech 8/9/2022